Commentary

Video

Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL

Author(s):

Consuelo Bertossi, MD
Conference|European Hematology Association Congress

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Consuelo Bertossi, MD, assistant doctor, Division of CLL, Department of Internal Medicine III, Universitätsklinikum Ulm, discusses research further elucidating the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia (CLL), as presented at the 2024 EHA Hybrid Congress.

Related Videos
Minoo Battiwalla, MD, MS
Cynthia X. Ma, MD, PhD
Jyoti Patel, MD
Leo I. Gordon, MD
Bertram Yuh, MD, MISM, MSHCPM
Alexander Drilon, MD
David Rimm, MD, PhD
Laahn Ho Foster, MD
David C. Fisher, MD
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Related Content
Gursel Aktan, MD, PhD
October 24th 2024

Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

David C. Fisher, MD, of Dana-Farber Cancer Institute
October 21st 2024

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Jorge Cortes, MD, of Georgia Cancer Center
October 21st 2024

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

Ribociclib in breast cancer | Image Credit: © Axel Kock - stock.adobe.com
October 18th 2024

Ribociclib Earns Positive CHMP Opinion in HR+/HER2– Early Breast Cancer